University of California, U. Vienna, Charpentier Awarded Fourth U.S. CRISPR-Cas9 Patent
A fourth U.S. patent covering CRISPR-Cas9 claims was granted today to the Regents of the University of California (UC), the University of Vienna, and CRISPR pioneer Emmanuelle Charpentier, PhD, director and scientific member at the Max Planck Institute of Infection Biology, Berlin.
U.S. Patent No. 10,266,850, “Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription,” focuses on systems and methods for using CRISPR/Cas9 technology in a single guide format, including uses to target and edit or modulate genes.
When those single molecule guide RNAs are combined with the Cas9 protein, they create efficient and effective tools for the targeting and editing of genes, UC said in a statement today.
